Driving performance assessments for benzodiazepine receptor agonist-related impairment: a scoping review protocol.
Journal
JBI evidence synthesis
ISSN: 2689-8381
Titre abrégé: JBI Evid Synth
Pays: United States
ID NLM: 101764819
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
10
11
2020
medline:
22
5
2021
entrez:
9
11
2020
Statut:
ppublish
Résumé
The objective of this scoping review is to identify, map, and characterize the evidence for assessments that measure driving performance in people taking benzodiazepine receptor agonists. Benzodiazepines and Z-drugs are widely prescribed for the treatment of anxiety disorders and insomnia even though they are not recommended as an initial treatment for these indications. Benzodiazepine and Z-drug use is associated with an elevated risk of traffic accidents, and guidance documents instruct patients to consult with their health care providers for instructions on how to safely operate a motor vehicle while consuming these medications. However, little is known about the assessments that measure driving performance regarding the extent and length of impairment from the consumption of the individual benzodiazepines and Z-drugs. Eligible studies will include participants who are new, intermittent, or chronic users of benzodiazepines and Z-drugs. No exclusions will be applied regarding the health status of participants or whether their benzodiazepine and Z-drug use is for an approved indication as indicated by government agencies (eg, Health Canada) or practice guidelines. Studies that examine the consumption of a benzodiazepine and Z-drug in association with the operation of a motor vehicle (real or simulated) with direct or indirect objective or standard subjective measures or indicators of impairment while operating a motor vehicle will be considered. Embase (Elsevier), MEDLINE (Ovid), and PsycINFO (EBSCO) will be searched as sources of published studies. Only studies published in English will be included, and there will be no limit on dates of publication. After screening the titles and abstracts of identified citations, two independent reviewers will retrieve potentially relevant full-text studies and extract data. Data will be presented in diagrammatic or tabular form accompanied by a narrative summary.
Identifiants
pubmed: 33165178
pii: 02174543-202101000-00016
doi: 10.11124/JBISRIR-D-19-00420
doi:
Substances chimiques
GABA-A Receptor Agonists
0
Receptors, GABA-A
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
242-250Informations de copyright
Copyright © 2021 JBI.
Déclaration de conflit d'intérêts
RMM is an associate editor for JBI Evidence Synthesis and was blinded to the processing and decision-making associated with this manuscript. The other authors declare no conflict of interest.
Références
Gustavsen I, Bramness JG, Skurtveit S, Engeland A, Neutel I, Mørland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, flunitrazepam and nitrazepam. Sleep Med 2008; 9 (8):818–822.
Organisation for Economic Co-operation and Development. Drugs and driving. Paris, France: OECD Publishing; 2010.
Qaseem A, Kansagara D, Forciea MA, Cooke M, Denberg TD. Clinical Guidelines Committee of the American College of Physicians. Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2016; 165 (2):125–133.
Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry 2014; 14 (1):S1.
Cunningham CM, Hanley GE, Morgan S. Patterns in the use of benzodiazepines in British Columbia: examining the impact of increasing research and guideline cautions against long-term use. Health Policy 2010; 97 (2–3):122–129.
Neutel CI, Skurtveit S, Berg C. What is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly population. Sleep Med 2012; 13 (7):893–897.
Kassam A, Patten SB. Hypnotic use in a population-based sample of over thirty-five thousand interviewed Canadians. Popul Health Metr 2006; 4:15.
Brett J, Maust DT, Bouck Z, Ignacio RV, Mecredy G, Kerr EA, et al. Benzodiazepine use in older adults in the United States, Ontario, and Australia from 2010 to 2016. J Am Geriatr Soc 2018; 66 (6):1180–1185.
Alessi-Severini S, Bolton JM, Enns MW, Dahl M, Collins DM, Chateau D, et al. Use of benzodiazepines and related drugs in Manitoba: a population-based study. CMAJ Open 2014; 2 (4):E208–E216.
Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med 2013; 173 (9):754–761.
Victorri-Vigneau C, Dailly E, Veyrac G, Jolliet P. Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. Br J Clin Pharmacol 2007; 64 (2):198–209.
Gomm W, von Holt K, Thome F, Broich K, Maier W, Weckbecker K, et al. Regular benzodiazepine and Z-substance use and risk of dementia: an analysis of German claims data. J Alzheimers Dis 2016; 54 (2):801–808.
Nakafero G, Sanders RD, Nguyen-Van-Tam JS, Myles PR. The association between benzodiazepines and influenza-like illness-related pneumonia and mortality: a survival analysis using UK Primary Care data. Pharmacoepidemiol Drug Saf 2016; 25 (11):1263–1273.
Gunja N. In the Zzz zone: the effects of Z-drugs on human performance and driving. J Med Toxicol Off J Am Coll Med Toxicol 2013; 9 (2):163–171.
U.S. Department of Transportation. Average annual miles per driver by age group [Internet]. 2018 [cited 30 Sep 2019]. Available from: https://www.fhwa.dot.gov/ohim/onh00/bar8.htm.
Transport Canada. Canadian motor vehicle traffic collision statistics: 2017 [Internet]. 2010 [cited 23 Aug 2019]. Available from: https://tc.canada.ca/en/canadian-motor-vehicle-traffic-collision-statistics-2017.
Neutel I. Benzodiazepine-related traffic accidents in young and elderly drivers. Hum Psychopharmacol Clin Exp 1998; 13 (S2):S115–S123.
Kriikku P, Hurme H, Wilhelm L, Rintatalo J, Hurme J, Kramer J, et al. Sedative-hypnotics are widely abused by drivers apprehended for driving under the influence of drugs. Ther Drug Monit 2015; 37 (3):339–346.
Department of Justice. Part 2: Offenses relating to conveyances – alcohol and drugs [Internet]. 2018 [cited 01 Oct 2019]. Available from: https://laws-lois.justice.gc.ca/eng/annualstatutes/2018_21/page-3.html.
Norwegian Ministry of Transport and Communications. Driving under the influence of non-alcohol drugs [Internet]. Norway: 2014 [cited 03 Oct 2019]. Available from: https://www.regjeringen.no/contentassets/61d8bf75d02e4b64ab0bfbea244b78d9/sd_ruspavirket_kjoring_net.pdf.
Canadian Pharmacists Association. CPhA Monograph Zopiclone. 2019.
Canadian Pharmacists Association. CPhA Monograph Benzodiazepines. RxTx. 2015.
First Databank Inc. Kroll Care: Apo-Lorazepam 1 mg (DIN: 00655759). 2019;(unpublished material).
Royal Pharmaceutical Society. Drugs and driving legislation: quick reference guide [Internet]. 2015 [cited 30 Sep 2019]. Available from: https://www.rpharms.com/resources/quick-reference-guides/new-drugs-and-driving-legislation.
Verster JC, Pandi-Perumal SR, Ramaekers JG, de Gier JJ. Drugs, driving, and traffic safety. Basel: Birkhauser; 2009.
Verster JC, Roth T. Excursions out-of-lane versus standard deviation of lateral position as outcome measure of the on-the-road driving test. Hum Psychopharmacol 2014; 29 (4):322–329.
Verster JC, Mets MAJ. Psychoactive medication and traffic safety. Int J Environ Res Public Health 2009; 6 (3):1041–1054.
Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc 2015; 13 (3):141–146.
Peters MDJ, Godfrey C, McInerney P, Munn Z, Tricco AC, Khalil H. Aromataris E, Munn Z. Chapter 11: Scoping Reviews. JBI, JBI Reviewer's Manual [Internet]. Adelaide: 2017.
Moher D, Liberati A, Tetzlaff J, Altman DG. the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6 (7):e1000097.
Munn Z, Aromataris E, Tufanaru C, Stern C, Porritt K, Farrow J, et al. The development of software to support multiple systematic review types: the Joanna Briggs Institute System for the Unified Management, Assessment and Review of Information (JBI SUMARI). Int J Evid Based Healthc 2019; 17 (1):1000.